BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

438 related articles for article (PubMed ID: 10086733)

  • 21. Standardizing minimal residual disease by flow cytometry for precursor B lineage acute lymphoblastic leukemia in a developing country.
    Patkar N; Alex AA; B B; Ahmed R; Abraham A; George B; Vishwabandya A; Srivastava A; Mathews V
    Cytometry B Clin Cytom; 2012 Jul; 82(4):252-8. PubMed ID: 22467604
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Flow cytometric detection of rare normal human marrow cells with immunophenotypes characteristic of acute lymphoblastic leukemia cells.
    Hurwitz CA; Gore SD; Stone KD; Civin CI
    Leukemia; 1992 Apr; 6(4):233-9. PubMed ID: 1375301
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multiparameter flow cytometric analysis of human fetal bone marrow B cells.
    LeBien TW; Wörmann B; Villablanca JG; Law CL; Steinberg LM; Shah VO; Loken MR
    Leukemia; 1990 May; 4(5):354-8. PubMed ID: 1697009
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Comparison of the immunophenotype of patients with B lineage acute lymphoblastic leukemia at diagnosis and relapse].
    Liu YR; Chang Y; Fu JY; Cheng YF; Zhang LP; Li LD; Wang H; Liu GL; Chen SS; Huang XJ; Lu DP
    Zhonghua Xue Ye Xue Za Zhi; 2006 May; 27(5):335-8. PubMed ID: 16875586
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Developmental hierarchy during early human B-cell ontogeny after autologous bone marrow transplantation using autografts depleted of CD19+ B-cell precursors by an anti-CD19 pan-B-cell immunotoxin containing pokeweed antiviral protein.
    Uckun FM; Haissig S; Ledbetter JA; Fidler P; Myers DE; Kuebelbeck V; Weisdorf D; Gajl-Peczalska K; Kersey JH; Ramsay NK
    Blood; 1992 Jun; 79(12):3369-79. PubMed ID: 1375851
    [TBL] [Abstract][Full Text] [Related]  

  • 26. BIOMED-1 concerted action report: flow cytometric characterization of CD7+ cell subsets in normal bone marrow as a basis for the diagnosis and follow-up of T cell acute lymphoblastic leukemia (T-ALL).
    Porwit-MacDonald A; Björklund E; Lucio P; van Lochem EG; Mazur J; Parreira A; van den Beemd MW; van Wering ER; Baars E; Gaipa G; Biondi A; Ciudad J; van Dongen JJ; San Miguel JF; Orfao A
    Leukemia; 2000 May; 14(5):816-25. PubMed ID: 10803512
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A limited antibody panel can distinguish B-precursor acute lymphoblastic leukemia from normal B precursors with four color flow cytometry: implications for residual disease detection.
    Weir EG; Cowan K; LeBeau P; Borowitz MJ
    Leukemia; 1999 Apr; 13(4):558-67. PubMed ID: 10214862
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Leukemia-associated immunophenotypes in 415 childhood and adult patients with B lineage acute lymphoblastic leukemia by multiparametric flow cytometry analysis].
    Liu YR; Chen SS; Chang Y; Fu JY; Zhang LP; Wang H; Li LD; Zhu HH; Liu GL; Lu DP; Huang XJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Oct; 14(5):853-7. PubMed ID: 17096875
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CD19 negative precursor B acute lymphoblastic leukemia (B-ALL)-Immunophenotypic challenges in diagnosis and monitoring: A study of three cases.
    Ghodke K; Bibi A; Rabade N; Patkar N; Subramanian PG; Kadam PA; Badrinath Y; Ghogale S; Gujral S; Tembhare P
    Cytometry B Clin Cytom; 2017 Jul; 92(4):315-318. PubMed ID: 27018867
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Detection of residual disease in pediatric B-cell precursor acute lymphoblastic leukemia by comparative phenotype mapping: a study of five cases controlled by genetic methods.
    Dworzak MN; Stolz F; Fröschl G; Printz D; Henn T; Fischer S; Fleischer C; Haas OA; Fritsch G; Gadner H; Panzer-Grümayer ER
    Exp Hematol; 1999 Apr; 27(4):673-81. PubMed ID: 10210325
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Regenerating normal B-cell precursors during and after treatment of acute lymphoblastic leukaemia: implications for monitoring of minimal residual disease.
    van Wering ER; van der Linden-Schrever BE; Szczepański T; Willemse MJ; Baars EA; van Wijngaarde-Schmitz HM; Kamps WA; van Dongen JJ
    Br J Haematol; 2000 Jul; 110(1):139-46. PubMed ID: 10930991
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of CD81 and CD58 in minimal residual disease detection in pediatric B lymphoblastic leukemia.
    Tsitsikov E; Harris MH; Silverman LB; Sallan SE; Weinberg OK
    Int J Lab Hematol; 2018 Jun; 40(3):343-351. PubMed ID: 29500862
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The significance of peripheral blood minimal residual disease to predict early disease response in patients with B-cell acute lymphoblastic leukemia.
    Setiadi A; Owen D; Tsang A; Milner R; Vercauteren S
    Int J Lab Hematol; 2016 Oct; 38(5):527-34. PubMed ID: 27339737
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Quantitative flow cytometry can distinguish between normal and leukaemic B-cell precursors.
    Farahat N; Lens D; Zomas A; Morilla R; Matutes E; Catovsky D
    Br J Haematol; 1995 Nov; 91(3):640-6. PubMed ID: 8555067
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Detection of minimal residual disease in childhood B-acute lymphoblastic leukemia by 4-color flowcytometry.
    Baraka A; Sherief LM; Kamal NM; Shorbagy SE
    Int J Hematol; 2017 Jun; 105(6):784-791. PubMed ID: 28324281
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CD34+CD38+CD19+ as well as CD34+CD38-CD19+ cells are leukemia-initiating cells with self-renewal capacity in human B-precursor ALL.
    Kong Y; Yoshida S; Saito Y; Doi T; Nagatoshi Y; Fukata M; Saito N; Yang SM; Iwamoto C; Okamura J; Liu KY; Huang XJ; Lu DP; Shultz LD; Harada M; Ishikawa F
    Leukemia; 2008 Jun; 22(6):1207-13. PubMed ID: 18418410
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of new markers for minimal residual disease monitoring in B-cell precursor acute lymphoblastic leukemia: CD73 and CD86 are the most relevant new markers to increase the efficacy of MRD 2016; 00B: 000-000.
    Tembhare PR; Ghogale S; Ghatwai N; Badrinath Y; Kunder N; Patkar NV; Bibi AR; Chatterjee G; Arora B; Narula G; Banawali S; Deshpande N; Amare P; Gujral S; Subramanian PG
    Cytometry B Clin Cytom; 2018 Jan; 94(1):100-111. PubMed ID: 27718302
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CD34+ cell subpopulations detected by 8-color flow cytometry in bone marrow and in peripheral blood stem cell collections: application for MRD detection in leukemia patients.
    Björklund E; Gruber A; Mazur J; Mårtensson A; Hansson M; Porwit A
    Int J Hematol; 2009 Oct; 90(3):292-302. PubMed ID: 19728029
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunophenotypic differentiation patterns of normal hematopoiesis in human bone marrow: reference patterns for age-related changes and disease-induced shifts.
    van Lochem EG; van der Velden VH; Wind HK; te Marvelde JG; Westerdaal NA; van Dongen JJ
    Cytometry B Clin Cytom; 2004 Jul; 60(1):1-13. PubMed ID: 15221864
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A novel flow cytometric assay for detection of residual disease in patients with B-lymphoblastic leukemia/lymphoma post anti-CD19 therapy.
    Cherian S; Miller V; McCullouch V; Dougherty K; Fromm JR; Wood BL
    Cytometry B Clin Cytom; 2018 Jan; 94(1):112-120. PubMed ID: 27598971
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.